enzastaurin has been researched along with carboplatin in 5 studies
| Studies (enzastaurin) | Trials (enzastaurin) | Recent Studies (post-2010) (enzastaurin) | Studies (carboplatin) | Trials (carboplatin) | Recent Studies (post-2010) (carboplatin) |
|---|---|---|---|---|---|
| 188 | 52 | 99 | 12,895 | 4,001 | 5,244 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amant, F; Bauknecht, T; Darstein, C; Kania, M; Michel, AL; Musib, L; Oskay-Oezcelik, G; Sehouli, J; Vergote, I | 1 |
| Amant, F; Cadron, I; Drijkoningen, K; Leunen, K; Luyten, C; Mihalyi, A; Van Gorp, T; Vergote, I | 1 |
| Bradford, D; Bufill, J; Casey, EM; Fisher, W; Hanna, N; Harb, W; Latz, JE; Li, X; Nattam, S; Patel, J; Wu, J | 1 |
| Asmar, L; Barrera, D; Bromund, J; Choksi, JK; Couch, LS; Jotte, R; Kocs, DM; Obasaju, CK; Patt, DA; Peng, G; Periman, PO; Pritchard, S; Raju, RN; Rousey, SR; Schlossberg, HR; Socinski, MA; Stinchcombe, T; Treat, J; Wang, Y; Weissman, CH | 1 |
| Amant, F; Bauknecht, T; Casado, A; Chekerov, R; Emerich, J; Harter, P; Mansouri, K; Myrand, SP; Nguyen, TS; Sehouli, J; Shi, P; Vergote, IB | 1 |
4 trial(s) available for enzastaurin and carboplatin
| Article | Year |
|---|---|
Carboplatin and paclitaxel in combination with oral enzastaurin in advanced ovarian or primary peritoneal cancer: results from a safety lead-in study.
Topics: Administration, Oral; Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Disease Progression; Drug Interactions; Female; Humans; Indoles; Middle Aged; Neoadjuvant Therapy; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms | 2009 |
Randomized, double-blinded, multicenter, phase II study of pemetrexed, carboplatin, and bevacizumab with enzastaurin or placebo in chemonaïve patients with stage IIIB/IV non-small cell lung cancer: Hoosier Oncology Group LUN06-116.
Topics: Adenocarcinoma; Adrenal Gland Neoplasms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Carboplatin; Double-Blind Method; Female; Glutamates; Guanine; Humans; Indoles; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Placebos; Pleural Neoplasms; Survival Rate; Treatment Outcome | 2010 |
Randomized, phase II trial of pemetrexed and carboplatin with or without enzastaurin versus docetaxel and carboplatin as first-line treatment of patients with stage IIIB/IV non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Glutamates; Guanine; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Quality of Life | 2010 |
Randomized, phase II, placebo-controlled, double-blind study with and without enzastaurin in combination with paclitaxel and carboplatin as first-line treatment followed by maintenance treatment in advanced ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Double-Blind Method; Female; Humans; Indoles; Middle Aged; Ovarian Neoplasms; Paclitaxel; Protein Kinase C; Protein Kinase C beta | 2013 |
1 other study(ies) available for enzastaurin and carboplatin
| Article | Year |
|---|---|
The impact of enzastaurin (LY317615.HCl) on CA125 biosynthesis and shedding in ovarian cancer cells.
Topics: Antineoplastic Agents; Apoptosis; CA-125 Antigen; Carboplatin; Cell Growth Processes; Cell Line, Tumor; Dose-Response Relationship, Drug; Female; Humans; Indoles; Ovarian Neoplasms; Paclitaxel | 2010 |